Literature DB >> 9398659

Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells.

P Gutiérrez1, M D Delgado, C Richard, F Moreau-Gachelin, J León.   

Abstract

The human K562 cell line is derived from a chronic myelogenous leukemia in blastic crisis. Treatment of K562 cells with interferons alpha, beta or gamma resulted in inhibition of cell proliferation. Spi-1/PU.1 is a transcription factor of the Ets family which is required for normal hematopoyesis. We have found that spi-1 mRNA and protein as well as Spi-1-DNA binding activity increase after exposure of K562 cells to interferons. The increase in spi-1 expression ranged from 4- to 8-fold with the different interferons. K562 cells can be differentiated in vitro towards erythroid cells or monocyte-macrophage cells. Interestingly, the regulation of spi-1 by interferon-alpha depended on the differentiated phenotype of K562 cells: interferon-alpha failed to induce spi-1 in erythroid differentiated cells, whereas it induced spi-1 in monocyte-macrophage differentiated cells. The results suggest a role for Spi-1 in the cytostatic response to interferons.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398659     DOI: 10.1006/bbrc.1997.7760

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.

Authors:  M Horita; E J Andreu; A Benito; C Arbona; C Sanz; I Benet; F Prosper; J L Fernandez-Luna
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

Review 2.  Direct Inhibition of IRF-Dependent Transcriptional Regulatory Mechanisms Associated With Disease.

Authors:  Aleksandra Antonczyk; Bart Krist; Malgorzata Sajek; Agata Michalska; Anna Piaszyk-Borychowska; Martyna Plens-Galaska; Joanna Wesoly; Hans A R Bluyssen
Journal:  Front Immunol       Date:  2019-05-24       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.